

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>mTOR inhibitors in cancer therapy | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2078/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2078" />
    
            <meta name="description" content="Read the original article in full on F1000Research: mTOR inhibitors in cancer therapy" />
    
            <meta name="og:title" content="F1000Research Article: mTOR inhibitors in cancer therapy.">
            <meta name="og:description" content="Read the latest article version by Jianling Xie, Xuemin Wang, Christopher G. Proud, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="9910">
            <meta name="article-id" content="9207">
            <meta name="dc.title" content="mTOR inhibitors in cancer therapy">
            <meta name="dc.description" content="The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers. Inhibiting mTORC1 signaling has therefore attracted great attention as an anti-cancer therapy. However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.">
            <meta name="dc.subject" content="mTOR, rapamycin, mTOR inhibitors, cancer therapy, ">
            <meta name="dc.creator" content="Xie, Jianling">
            <meta name="dc.creator" content="Wang, Xuemin">
            <meta name="dc.creator" content="Proud, Christopher G.">
            <meta name="dc.date" content="2016/08/25">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9207.1">
            <meta name="dc.source" content="F1000Research 2016 5:2078">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="mTOR ">
            <meta name="prism.keyword" content=" rapamycin ">
            <meta name="prism.keyword" content=" mTOR inhibitors ">
            <meta name="prism.keyword" content=" cancer therapy ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/08/25">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2078">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9207.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2078">
            <meta name="citation_title" content="mTOR inhibitors in cancer therapy">
            <meta name="citation_abstract" content="The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers. Inhibiting mTORC1 signaling has therefore attracted great attention as an anti-cancer therapy. However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.">
            <meta name="citation_description" content="The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers. Inhibiting mTORC1 signaling has therefore attracted great attention as an anti-cancer therapy. However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.">
            <meta name="citation_keywords" content="mTOR, rapamycin, mTOR inhibitors, cancer therapy, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jianling Xie">
            <meta name="citation_author_institution" content="Nutrition and Metabolism, South Australian Health and Medical research Institute, Adelaide, SA, Australia">
            <meta name="citation_author" content="Xuemin Wang">
            <meta name="citation_author_institution" content="Nutrition and Metabolism, South Australian Health and Medical research Institute, Adelaide, SA, Australia">
            <meta name="citation_author_institution" content="School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia">
            <meta name="citation_author" content="Christopher G. Proud">
            <meta name="citation_author_institution" content="Nutrition and Metabolism, South Australian Health and Medical research Institute, Adelaide, SA, Australia">
            <meta name="citation_author_institution" content="School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia">
            <meta name="citation_publication_date" content="2016/08/25">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2078">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9207.1">
            <meta name="citation_firstpage" content="2078">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2078/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2078.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=9910 /> <input type=hidden id=articleId name=articleId value=9207 /> <input type=hidden id=xmlUrl value="/articles/5-2078/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2078-v1.xml"> <input type=hidden id=article_uuid value=3c0c7d27-4a00-4574-a4fb-aac030823eb5 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="mTOR inhibitors in cancer therapy"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9207.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9207.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2078"
  },
  "headline": "mTOR inhibitors in cancer therapy",
  "datePublished": "2016-08-25T15:29:54",
  "dateModified": "2016-08-25T15:29:54",
  "author": [
    {
      "@type": "Person",
      "name": "Jianling Xie"
    },    {
      "@type": "Person",
      "name": "Xuemin Wang"
    },    {
      "@type": "Person",
      "name": "Christopher G. Proud"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers. Inhibiting mTORC1 signaling has therefore attracted great attention as an anti-cancer therapy. However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2078/v1",
            "name": "mTOR inhibitors in cancer therapy"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> mTOR inhibitors in cancer therapy </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=9910 data-id=9207 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9207.1" data-recommended="" data-doi="10.12688/f1000research.9207.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2078/v1/pdf?article_uuid=3c0c7d27-4a00-4574-a4fb-aac030823eb5" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9207-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9207-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9207-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Xie J, Wang X and Proud CG. mTOR inhibitors in cancer therapy [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2078 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9207.1" target=_blank>https://doi.org/10.12688/f1000research.9207.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9207-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9207 id=track-article-signin-9207 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9207?target=/articles/5-2078/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9910 /> <input name=articleId type=hidden value=9207 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>mTOR inhibitors in cancer therapy</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Jianling Xie<a href="https://orcid.org/0000-0002-0588-8016" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0588-8016</div><sup>1</sup>,&nbsp;</span><span class="">Xuemin Wang<sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:christopher.proud@sahmri.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Christopher G. Proud</span></a><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Jianling Xie<a href="http://orcid.org/0000-0002-0588-8016" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0588-8016</div><sup>1</sup>,&nbsp;</span><span class="">Xuemin Wang<sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:christopher.proud@sahmri.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Christopher G. Proud</span></a><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 25 Aug 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9207.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Nutrition and Metabolism, South Australian Health and Medical research Institute, Adelaide, SA, Australia<br/> <sup>2</sup> School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16708-15891></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16707-15892></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=2001-15893></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers. Inhibiting mTORC1 signaling has therefore attracted great attention as an anti-cancer therapy. However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> mTOR, rapamycin, mTOR inhibitors, cancer therapy, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Christopher G. Proud (<a href="mailto:christopher.proud@sahmri.com">christopher.proud@sahmri.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Christopher G. Proud </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Xie J <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Xie J, Wang X and Proud CG. mTOR inhibitors in cancer therapy [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2078 (<a href="https://doi.org/10.12688/f1000research.9207.1" target=_blank>https://doi.org/10.12688/f1000research.9207.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 25 Aug 2016, <b>5</b>(F1000 Faculty Rev):2078 (<a href="https://doi.org/10.12688/f1000research.9207.1" target=_blank>https://doi.org/10.12688/f1000research.9207.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 25 Aug 2016, <b>5</b>(F1000 Faculty Rev):2078 (<a href="https://doi.org/10.12688/f1000research.9207.1" target=_blank>https://doi.org/10.12688/f1000research.9207.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d4428e170>A brief introduction to the mTOR pathway</h2><p class="" id=d4428e173>mTOR (the mammalian or mechanistic target of rapamycin) is a protein kinase that forms two distinct types of multiprotein complex, termed mTOR complexes 1 and 2 (mTORC1 and mTORC2). Each plays key roles in cellular regulation<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>.</p><p class="" id=d4428e183>mTORC1 drives multiple anabolic pathways, including protein synthesis, ribosome production, lipogenesis, and nucleotide synthesis, all of which are important for cell and tissue growth<sup><a href="#ref-1">1</a></sup>. mTORC1 also suppresses a key catabolic process, autophagy<sup><a href="#ref-3">3</a></sup>, both by inhibiting its activation and by suppressing the production of lysosomes, the organelles in which autophagy occurs. mTORC1 phosphorylates proteins involved in all of these pathways, thereby altering their activities or subcellular localization<sup><a href="#ref-3">3</a></sup>. mTORC1 signaling is activated by several oncogenic pathways, including the Ras/Raf/MEK/ERK pathway and the phosphoinositide 3-kinase (PI3K)/AKT (PKB) pathway (<a href="#f1">Figure 1</a>), and by the intracellular availability of energy (ATP) and essential amino acids<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. A key negative upstream regulator of mTORC1 is a protein complex which includes TSC1 and TSC2 (<a href="#f1">Figure 1</a>)<sup><a href="#ref-6">6</a></sup>. Loss of the gene for TSC1 or TSC2 leads to a condition termed tuberous sclerosis complex (TSC), which is characterized by benign tumors<sup><a href="#ref-6">6</a></sup>.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9910/7e5abb1b-b20e-47a4-b658-a73f164b4561_figure1.gif"><img alt="7e5abb1b-b20e-47a4-b658-a73f164b4561_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9910/7e5abb1b-b20e-47a4-b658-a73f164b4561_figure1.gif"></a><div class=caption><h3>Figure 1. Schematic representation of signaling pathways involving the two mTOR complexes.</h3><p id=d4428e230>Typically, hormones and growth factors activate mTOR complex 1 (mTORC1) through the SOS/Ras/Raf-MEK-ERK (MAPK) or the IRS1/PI3K-PDK1-PKB pathways or both. mTORC2 also contributes to the activation of PKB through the direct phosphorylation of its turn motif as well as its hydrophobic motif. These pathways impinge on the tuberous sclerosis complex (TSC), which serves as a GTPase activator protein for the small G-protein Rheb. Upon inhibitory phosphorylation evoked by upstream kinases such as PKB, the activity of TSC is suppressed, promoting the accumulation of GTP-bound Rheb, which in turn activates mTORC1 on the surface of lysosomes. Amino acids also activate mTORC1 by bringing the latter onto lysosomes via the Rag GTPases. S6K-rpS6 and 4EBP1-eIF4E are the best-characterized mTORC1 downstream targets and are responsible for controlling a variety of anabolic effects driven by mTORC1. Dashed lines indicate feedback mechanisms. mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase.</p></div></div><p class="" id=d4428e237>In particular, mTORC1 signaling positively regulates a key component of the cell’s protein synthesis machinery, eukaryotic initiation factor eIF4E, which mediates the recruitment of ribosomes to mRNAs for their translation<sup><a href="#ref-7">7</a></sup>. Enhanced expression of eIF4E can transform cells and is seen in various human cancers<sup><a href="#ref-8">8</a></sup>. Adequate levels of eIF4E are required for tumorigenesis<sup><a href="#ref-8">8</a></sup>. Its function is blocked by small phosphoproteins termed eIF4E-binding proteins (4E-BPs). They are phosphorylated by mTORC1 and this induces their release from eIF4E, thereby alleviating such inhibition<sup><a href="#ref-7">7</a></sup>. There are other links from mTORC1 to the activation of protein synthesis and to the production of ribosomes<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>.</p><p class="" id=d4428e264>mTORC2 has distinct substrates from mTORC1<sup><a href="#ref-11">11</a></sup>, which include AKT (PKB)<sup><a href="#ref-12">12</a></sup>, a protein kinase that is involved in anabolic signaling (for example, in the activation of mTORC1<sup><a href="#ref-13">13</a>–<a href="#ref-15">15</a></sup> and in cell survival<sup><a href="#ref-16">16</a></sup>), and SGK1, whose function is rather less well understood. Owing to the lack of a specific inhibitor, much less is known about the control of mTORC2 than that of mTORC1. It may be linked to the PI3K pathway<sup><a href="#ref-17">17</a></sup>, which is frequently dysregulated in cancer, for example, by loss of the tumor suppressor protein PTEN (phosphatase and tensin homolog).</p><p class="" id=d4428e290>Given the many oncogenic pathways—and oncogenes or tumor suppressors—linked to mTOR signaling, it is estimated that mTORC1 function is hyperactivated in up to 70% of all human tumors<sup><a href="#ref-18">18</a></sup>. Equivalent information is not available for mTORC2, but its links to PI3K/PTEN suggest that it is also activated in tumor cells. This has stimulated a very high level of interest in targeting mTOR for cancer therapy; a search in PubMed for ‘mTOR inhibitors cancer therapy + review’ returns more than 1,000 hits.</p><p class="" id=d4428e297>These features have led to a very high level of interest—in academic labs and in the pharmaceutical industry—in targeting mTOR signaling as a potential therapeutic avenue for anti-cancer therapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4428e303>Rapamycin and the first generations of mTOR inhibitors</h2><p class="" id=d4428e306>The best-known inhibitor of mTOR is rapamycin, from which mTOR’s name derives. Rapamycin was originally applied as an immunosuppressant, blocking T-cell activation, and has been in use since around 2000 to prevent kidney graft rejection. However, rapamycin does not directly inhibit the catalytic (kinase) activity of mTOR; instead it binds, together with a small protein, an immunophilin termed FKBP12, specifically to mTORC1, but not mTORC2, to a domain adjacent to the kinase active site (<a href="#f2">Figure 2</a>). As a consequence, it inhibits only some of the functions of mTORC1. The data suggest that its effect on mTORC1 activity affects mainly weaker mTORC1 substrates, such as the protein kinase termed ribosomal protein rpS6 kinase, whereas it has only a limited, if any, effect on other, better substrates such as the eIF4E-binding protein 4E-BP1<sup><a href="#ref-19">19</a></sup>. The extent of its effect on this latter substrate appears to vary between cell types. In contrast to a previous report by Yip <i>et al</i>.<sup><a href="#ref-20">20</a></sup>, which showed that rapamycin treatment results in destabilization of the hollow lozenge-shaped mTORC1 dimer, a recent high-resolution cryo-electron microscopy study from Aylett <i>et al</i>.<sup><a href="#ref-21">21</a></sup> showed that the binding of rapamycin-FKBP12 to mTOR does not destabilize the mTORC1 dimer but rather reduces the access to the active site cleft from a width of 20 to 10 Å, implying that the FKBP12-rapamycin binding (FRB) domain acts as a gatekeeper of the active substrate binding site (discussed in <a href="#ref-22">22</a>). This may well explain why rapamycin differentially affects the phosphorylation of ‘stronger’ versus ‘weaker’ substrates.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9910/7e5abb1b-b20e-47a4-b658-a73f164b4561_figure2.gif"><img alt="7e5abb1b-b20e-47a4-b658-a73f164b4561_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9910/7e5abb1b-b20e-47a4-b658-a73f164b4561_figure2.gif"></a><div class=caption><h3>Figure 2. Domains of the mTOR protein and three generations of mTOR inhibitors.</h3><p id=d4428e344>mTOR is composed of 2,549 amino acids which can be divided into several structural domains, including HEAT (for anti-parallel α-helices found in <span style="text-decoration: underline">H</span>untingtin, <span style="text-decoration: underline">e</span>longation factor 3, PP2<span style="text-decoration: underline">A</span> and <span style="text-decoration: underline">T</span>OR1) repeats and FAT (for FRAP, ATM, TRAP), FRB, kinase, and FATC (for <i>C</i>-terminal FAT) domains. The HEAT repeats, located close to the <i>N</i>-terminus of mTOR, are required for mTOR multimerization. The FRB—FK506 binding protein 12 (FKBP12)–rapamycin binding—domain, as its name implies, is the binding site of mTOR to FKBP12 and rapamycin. FAT, kinase, and FATC domains are conserved within the phosphatidylinositol 3-kinase-related kinases (PIKKs) and are essential for maintaining the activity of PIKKs. The first-generation mTOR inhibitors, including rapamycin itself, bind to FKBP12, which in turn interacts with the FRB domain of mTOR to inhibit mTOR activity. The second-generation mTOR inhibitors are ATP-competitive mTOR inhibitors which act as ATP analogues and compete with ATP for the binding to the kinase domain of mTOR. The newly developed third generation of mTOR inhibitors can potentially overcome the drug resistance of cancer cells bearing mTOR FRB/kinase domain mutation; that is, FRB domain mutations (mTOR<sup>A2034V</sup> and mTOR<sup>F2108L</sup>) confer resistance to rapalogs (first generation), and a kinase domain mutation (mTOR<sup>M2327I</sup>) renders resistance to mTOR-KIs (second generation). mTOR, mammalian target of rapamycin.</p></div></div><p class="" id=d4428e379>4E-BP1 is the substrate through which mTORC1 controls cell proliferation<sup><a href="#ref-23">23</a></sup>, so the resistance of its phosphorylation to rapamycin likely contributes to the poor efficiency of rapamycin as an anti-hyperplastic agent. Another confounding factor is that, by impairing mTORC1, rapamycin can promote growth factor signaling via various feedback loops which, for example, promote activation of the oncogenic PI3K/Akt pathway<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. In addition, rapamycin is generally not cytotoxic, acting instead as a cytostatic agent. It can cause the upregulation of the pro-oncogenic protein eIF4E and promote other tumorigenic events (reviewed in <a href="#ref-26">26</a>). Tumors expressing high levels of eIF4E are likely to be less sensitive to mTOR inhibitors since levels of eIF4E may exceed those of the mTORC1-regulated inhibitor protein 4E-BP1. Inhibition of mTORC1 will also activate its downstream effector, eukaryotic elongation factor 2 kinase (eEF2K), which can promote cell survival<sup><a href="#ref-27">27</a></sup>.</p><p class="" id=d4428e400>As noted, it is very common that cellular signaling pathways involving the mTOR complexes are abnormally upregulated in cancer. Although rapamycin is a highly selective inhibitor against mTOR, it does not completely inhibit all of the activities of mTORC1<sup><a href="#ref-28">28</a></sup> and will inhibit mTORC2 in only some types of cells upon prolonged treatment<sup><a href="#ref-29">29</a></sup>. Although rapamycin does not interact with mTORC2, it can affect mTORC2 indirectly. By binding to mTOR as a complex with FKBP12, it prevents mTOR from associating with the mTORC2-specific partner protein Rictor, therefore causing a gradual decline in mTORC2 levels<sup><a href="#ref-29">29</a></sup>. The rate at which this occurs will depend on the rate of turnover of mTORC2 under given conditions but can occur within 1 or 2 days of treatment of cells with rapamycin and may account for some of the longer-term effects of rapamycin<sup><a href="#ref-29">29</a></sup>. Also, S6K can phosphorylate Rictor and thereby impair mTORC2 function, an effect that should be reversed by rapamycin<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>. These opposing effects are important considerations when interpreting—or trying to predict—the consequences of rapamycin treatment.</p><p class="" id=d4428e427>The pharmacological properties of rapamycin itself are not ideal, leading to the development and application of rapamycin analogs (rapalogs) with superior characteristics. Several such compounds have been developed and evaluated for their efficacy in treating diseases, including cancers (<a href="#f2">Figure 2</a> and <a href="#f3">Figure 3</a> and <a href="#T1">Table 1</a>). These are semi-synthetic rapamycin analogues which have been typically derivatized at the C-43 position on the cyclohexane outside the macrolide ring in order to improve aqueous solubility and suit oral administration. This also provides a more advantageous intellectual property position than for rapamycin itself. For example, RAD001 (everolimus)<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>, developed by Novartis as an immunosuppressive and anti-cancer drug (<a href="#T1">Table 1</a>), is a hydroxyethyl ether-derivative. CCI-779 (temsirolimus; Wyeth-Ayerst/Pfizer) and AP23573 (ridaforolimus or deforolimus; Merck/Ariad) also belong to this category.</p><div class="fig panel clearfix"><a name=f3 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9910/7e5abb1b-b20e-47a4-b658-a73f164b4561_figure3.gif"><img alt="7e5abb1b-b20e-47a4-b658-a73f164b4561_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9910/7e5abb1b-b20e-47a4-b658-a73f164b4561_figure3.gif"></a><div class=caption><h3>Figure 3. Selected examples of three generations of mTOR inhibitors and dual PI3K/mTOR inhibitors.</h3><p id=d4428e459>Chemical structures were drawn by using the website <a target=xrefwindow href="http://www.emolecules.com" id=d4428e461>www.emolecules.com</a>. mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase.</p></div></div><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Examples of the three generations of rapalogs/dual mTOR/PI3K inhibitors and their effects on human diseases.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4428e480 class=n-a></a><thead><a name=d4428e482 class=n-a></a><tr><a name=d4428e484 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d4428e486 class=n-a></a>Generation</th><th align=left colspan=1 rowspan=1><a name=d4428e489 class=n-a></a>Compound name</th><th align=left colspan=1 rowspan=1><a name=d4428e492 class=n-a></a>Approved year or<br class=br>current phase</th><th align=left colspan=1 rowspan=1><a name=d4428e497 class=n-a></a>Developer</th><th align=left colspan=1 rowspan=1><a name=d4428e500 class=n-a></a>Examples of indications in<br class=br>completed clinical trials</th><th align=left colspan=1 rowspan=1><a name=d4428e506 class=n-a></a>Reference</th></tr></thead><tbody><a name=d4428e511 class=n-a></a><tr><a name=d4428e513 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e515 class=n-a></a>1st</td><td colspan=1 rowspan=1><a name=d4428e518 class=n-a></a>Rapamycin (sirolimus)</td><td colspan=1 rowspan=1><a name=d4428e521 class=n-a></a>1999</td><td colspan=1 rowspan=1><a name=d4428e524 class=n-a></a>Wyeth-Ayerst</td><td colspan=1 rowspan=1><a name=d4428e527 class=n-a></a>Acute renal allograft rejection/<br class=br>restenosis</td><td colspan=1 rowspan=1><a name=d4428e533 class=n-a></a><a href="#ref-77">77</a>–<a href="#ref-80">80</a></td></tr><tr><a name=d4428e541 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e543 class=n-a></a>1st</td><td colspan=1 rowspan=1><a name=d4428e546 class=n-a></a>RAD001 (everolimus)</td><td colspan=1 rowspan=1><a name=d4428e549 class=n-a></a>2003–2011</td><td colspan=1 rowspan=1><a name=d4428e552 class=n-a></a>Novartis</td><td colspan=1 rowspan=1><a name=d4428e555 class=n-a></a>Allograft rejection/advanced kidney<br class=br>cancer/ tuberous sclerosis/advanced<br class=br>RCC/pNET/<br class=br>neurofibromatosis</td><td colspan=1 rowspan=1><a name=d4428e565 class=n-a></a><a href="#ref-32">32</a>,<a href="#ref-33">33</a></td></tr><tr><a name=d4428e573 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e575 class=n-a></a>1st</td><td colspan=1 rowspan=1><a name=d4428e578 class=n-a></a>CCI-779 (temsirolimus)</td><td colspan=1 rowspan=1><a name=d4428e581 class=n-a></a>2007–2008</td><td colspan=1 rowspan=1><a name=d4428e584 class=n-a></a>Wyeth-Ayerst/Pfizer</td><td colspan=1 rowspan=1><a name=d4428e587 class=n-a></a>Advanced RCC/mantle cell<br class=br>lymphoma</td><td colspan=1 rowspan=1><a name=d4428e593 class=n-a></a><a href="#ref-81">81</a></td></tr><tr><a name=d4428e598 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e600 class=n-a></a>DI</td><td colspan=1 rowspan=1><a name=d4428e603 class=n-a></a>NVP-BEZ235 (dactolisib)</td><td colspan=1 rowspan=1><a name=d4428e606 class=n-a></a>Phase I/II (22)</td><td colspan=1 rowspan=1><a name=d4428e609 class=n-a></a>Novartis</td><td colspan=1 rowspan=1><a name=d4428e612 class=n-a></a>MBC/pNET</td><td colspan=1 rowspan=1><a name=d4428e616 class=n-a></a><a href="#ref-35">35</a></td></tr><tr><a name=d4428e621 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e623 class=n-a></a>DI</td><td colspan=1 rowspan=1><a name=d4428e626 class=n-a></a>GSK2126458</td><td colspan=1 rowspan=1><a name=d4428e629 class=n-a></a>Phase I/II (3)</td><td colspan=1 rowspan=1><a name=d4428e632 class=n-a></a>GlaxoSmithKline</td><td colspan=1 rowspan=1><a name=d4428e635 class=n-a></a>Advanced solid tumors, lymphoma</td><td colspan=1 rowspan=1><a name=d4428e639 class=n-a></a><a href="#ref-38">38</a></td></tr><tr><a name=d4428e645 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e647 class=n-a></a>DI</td><td colspan=1 rowspan=1><a name=d4428e650 class=n-a></a>XL765</td><td colspan=1 rowspan=1><a name=d4428e653 class=n-a></a>Phase I/II (5)</td><td colspan=1 rowspan=1><a name=d4428e656 class=n-a></a>Sanofi-Aventis, Exelixis</td><td colspan=1 rowspan=1><a name=d4428e659 class=n-a></a>Glioblastoma multiforme/NSCLC/<br class=br>MBC</td><td colspan=1 rowspan=1><a name=d4428e665 class=n-a></a><a href="#ref-39">39</a></td></tr><tr><a name=d4428e670 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e672 class=n-a></a>2nd</td><td colspan=1 rowspan=1><a name=d4428e675 class=n-a></a>AZD8055</td><td colspan=1 rowspan=1><a name=d4428e678 class=n-a></a>Phase I/II (5)</td><td colspan=1 rowspan=1><a name=d4428e681 class=n-a></a>AstraZeneca</td><td colspan=1 rowspan=1><a name=d4428e684 class=n-a></a>Advanced solid tumors/glioma/HCC</td><td colspan=1 rowspan=1><a name=d4428e688 class=n-a></a><a href="#ref-50">50</a></td></tr><tr><a name=d4428e693 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e695 class=n-a></a>2nd</td><td colspan=1 rowspan=1><a name=d4428e698 class=n-a></a>INK128/MLN0128</td><td colspan=1 rowspan=1><a name=d4428e701 class=n-a></a>Phase I/II (25)</td><td colspan=1 rowspan=1><a name=d4428e704 class=n-a></a>Intellikine</td><td colspan=1 rowspan=1><a name=d4428e707 class=n-a></a>Advanced solid tumors/multiple<br class=br>myeloma/Waldenstrom<br class=br>macroglobulinemia</td><td colspan=1 rowspan=1><a name=d4428e715 class=n-a></a><a href="#ref-44">44</a></td></tr><tr><a name=d4428e720 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e722 class=n-a></a>2nd</td><td colspan=1 rowspan=1><a name=d4428e725 class=n-a></a>OSI027</td><td colspan=1 rowspan=1><a name=d4428e728 class=n-a></a>Phase I/II (1)</td><td colspan=1 rowspan=1><a name=d4428e731 class=n-a></a>OSI Pharmaceuticals</td><td colspan=1 rowspan=1><a name=d4428e734 class=n-a></a>Advanced solid tumors/lymphoma</td><td colspan=1 rowspan=1><a name=d4428e738 class=n-a></a><a href="#ref-82">82</a></td></tr><tr><a name=d4428e743 class=n-a></a><td colspan=1 rowspan=1><a name=d4428e745 class=n-a></a>3rd</td><td colspan=1 rowspan=1><a name=d4428e748 class=n-a></a>RapaLinks</td><td colspan=1 rowspan=1><a name=d4428e751 class=n-a></a>Developed in 2016</td><td colspan=1 rowspan=1><a name=d4428e754 class=n-a></a>Rodrik-Outmezguine <i>et al</i>.</td><td colspan=1 rowspan=1><a name=d4428e760 class=n-a></a>Tested in rapamycin- and AZD8055-<br class=br>resistant cell lines and mouse<br class=br>xenografts</td><td colspan=1 rowspan=1><a name=d4428e768 class=n-a></a><a href="#ref-74">74</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d4428e777 class=n-a></a><p id=d4428e779> For “current phase”, the number within the parentheses indicates the number of clinical trials currently being carried out or already withdrawn, completed, or terminated according to ClinicalTrials.gov. DI, dual mammalian target of rapamycin/phosphoinositide 3-kinase inhibitor; HCC, hepatocellular carcinoma; MBC, metastatic breast cancer; mTOR, mammalian target of rapamycin; NSCLC, non-small cell lung cancer; PI3K, phosphoinositide 3-kinase; pNET, pancreatic neuroendocrine tumor; RCC, renal cell carcinoma.</p></div></div></div><p class="" id=d4428e785>Despite the strong evidence that mTORC1 and mTORC2 control events that are important for cell growth and survival, which are processes of key importance in cancer cells, progress in successfully applying rapamycin and rapalogs as anti-cancer agents has been limited. Temsirolimus was approved by the US Food and Drug Administration for advanced renal cell carcinoma in 2007 and since then everolimus has been passed for use in certain other cancers, including neuroendocrine tumors and, as a combination therapy, HER2-positive breast cancer, as well as for certain TSC-related tumors (<a href="#T1">Table 1</a>). However, this relatively modest list contrasts to the immense amount of research effort devoted to studying mTORC1 signaling in tumors or cancer cells.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4428e794>Dual PI3K/mTOR inhibitors</h2><p class="" id=d4428e797>The FAT, FATC, and kinase domain of mTOR are widely conserved in a group of protein kinases which display prominent structural similarities to PIKK (PI3K-related kinases) (<a href="#f2">Figure 2</a> and <a href="#T1">Table 1</a>). As a result, it has been discovered that several PI3K inhibitors (including derivatives of the classic LY294002 and Wortmannin) developed during drug discovery projects can also effectively suppress the activation of both mTOR complexes. These are therefore classified as dual PI3K/mTOR inhibitors. As potential anti-cancer agents, they represent superior benefits in comparison with the first class of mTOR inhibitors because they simultaneously inhibit both PI3K and mTOR, two crucial signaling hubs that promote cancer cell growth. The first inhibitors that came out from this group of compounds were PI103 and its derivatives, named PI450 and PI620, which show further improvements to the pharmacokinetic properties of the parent molecule<sup><a href="#ref-34">34</a></sup>. Yet arguably the most successful example in clinical trials from this class of inhibitors is the imidazoquinoline derivative NVP-BEZ235<sup><a href="#ref-35">35</a></sup> developed by Novartis. Not only does the dual mTOR/PI3K inhibitor NVP-BEZ235 exert potent anti-tumor activity <i>in vivo</i> but its effect can be further enhanced by the combination with inhibitors against other mitogenic pathways, such as the MEK/ERK inhibitors<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. Other examples from this class of inhibitors include GSK2126458 from GlaxoSmithKline<sup><a href="#ref-38">38</a></sup>, XL765 from Sanofi-Aventis and Exelixis<sup><a href="#ref-39">39</a></sup>, and SF1126 from Semafore<sup><a href="#ref-40">40</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4428e840>Second-generation mTOR inhibitors</h2><p class="" id=d4428e843>Given the inability of rapamycin to affect all functions of mTORC1 and its inefficacy in anti-cancer therapy, several academic and pharmaceutical laboratories have developed compounds that inhibit the catalytic activity of mTOR itself. This means they can potentially inhibit all phosphorylation events catalyzed by mTORC1 but will also affect mTORC2. This finally gave rise to a second generation of mTOR inhibitors which are designed to act as ATP-competitive agents to mTOR. These inhibitors exhibit a much lower half-maximal inhibitory concentration (IC<sub>50</sub>) against mTOR activity than PI3K. The first such compound is the mTOR inhibitor PP242<sup><a href="#ref-41">41</a></sup>. As a classic indication of complete mTORC1 inhibition, the phosphorylation of the rapamycin-resistant sites in 4E-BP1 (Thr37/Thr46) is effectively blocked by PP242<sup><a href="#ref-42">42</a></sup>. PP242 also shows effectiveness against rapamycin-resistant PKB-driven tumorigenesis<sup><a href="#ref-43">43</a></sup>. INK128 (later renamed MLN0128) is a PP242 derivative developed by Intellikine<sup><a href="#ref-44">44</a></sup> and has been, or is being, tested in 25 clinical trials, according to ClinicalTrials.gov (<a href="#T1">Table 1</a>).</p><p class="" id=d4428e869>Within the same category, Torin 1<sup><a href="#ref-45">45</a></sup> and its sister compound Torin 2<sup><a href="#ref-46">46</a></sup> were synthesized from quinolone 1 by Nathanael Gray’s lab and developed by AstraZeneca. These compounds exhibit an IC<sub>50</sub> against mTOR of less than 10 nM (3 nM as for Torin 1) <i>in vitro</i>. Torin 2 not only exhibits approximately 100-fold selectivity relative to PI3K (IC<sub>50</sub> of approximately equal to 200 nM) and 100-fold selectivity over other kinases tested but also possesses enhanced bioavailability and stability. Ku-0063794 and Ku-0068650<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>, developed by KuDOS Pharmaceuticals (now part of AstraZeneca), are also examples of early ATP-competitive mTOR inhibitors which exhibit great anti-proliferative potential against cancer cells <i>in vitro</i>. Wyeth-Ayerst (now part of Pfizer) developed a series of dual mTORC1/2 inhibitors via high-throughput screening based on the parent compound WAY-001 and subsequently named them WAY-600, WYE-687, and WYE-354<sup><a href="#ref-49">49</a></sup>. These compounds also possess anti-proliferative effects on cancer cells and have similar IC<sub>50</sub> values toward mTOR as the Torin and Ku compounds and have reasonable selectivity for mTOR as compared to the PI3Ks (approximately 100-fold). Moreover, AZD8055 and AZD2014<sup><a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup> are two orally bioavailable compounds derived from the Ku compounds. They were developed by researchers from KuDOS Pharmaceuticals and later AstraZeneca. The effectiveness of these compounds in the inhibition of cancer cell growth has been tested in several cancer cell lines where they show an anti-proliferative IC<sub>50</sub> dose range of 20 to 50 nM<sup><a href="#ref-50">50</a></sup>. AZD2014 is currently being tested in combination with other inhibitors, including ibrutinib (which blocks B-cell receptor signaling), AZD6244 (a MEK inhibitor), paclitaxel (targets tubulin), and fulvestrant (estrogen receptor degrader), in phase I/II clinical trials against breast cancer, lung cancer, and lymphoma.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4428e925>Side effects of previous mTOR inhibitors and the birth of a new generation</h2><p class="" id=d4428e928>Despite the high efficiency in inhibiting the activity of both mTOR complexes, ATP-competitive mTOR inhibitors are still quite ineffective in our battle against cancer, potentially for several reasons. Firstly, the inhibition of mTORCs triggers a number of feedback loops toward upstream signaling pathways, activation of which may promote cancer cell survival and metastasis<sup><a href="#ref-31">31</a></sup>. These pathways have been discussed in some detail by Li <i>et al</i>.<sup><a href="#ref-26">26</a></sup>.</p><p class="" id=d4428e942>Secondly, mTOR signaling is essential for normal cell viability and its inhibition can be unavoidably detrimental to healthy tissues. For instance, sirolimus and tacrolimus were given as immunosuppressant drugs during pancreatic islet transplantations<sup><a href="#ref-52">52</a></sup>, yet a follow-up study 5 years later has demonstrated that only approximately 10% of the recipients remained insulin independent<sup><a href="#ref-53">53</a></sup>, likely owing to the fact that mTOR inhibitors would induce pancreatic β-cell death<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup> as a result of the inhibition of mTORC2<sup><a href="#ref-56">56</a></sup>. Important to note is that second-generation mTOR inhibitors, such as Torin 1, are actually more toxic to islet cells than rapamycin itself<sup><a href="#ref-56">56</a></sup>, potentially because of its rapid and complete suppressive action against both mTOR complexes. Furthermore, mTORC1 is a well-characterized as inhibiting of autophagy<sup><a href="#ref-3">3</a></sup>, and the induction of autophagy caused by mTOR inhibition may promote cancer cell survival. Indeed, AZD8055 is shown to activate autophagic flux in a variety of cancer cells<sup><a href="#ref-50">50</a>,<a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup> and the inhibition of autophagy was able to reverse the paradoxical cytoprotective effect of AZD8055 on colon carcinoma cells<sup><a href="#ref-57">57</a></sup>. Also, mTOR is a master positive regulator of mRNA translation, which is carried out by versatile high energy-consuming molecular machineries within the cell, and because energy saving is crucial for cancer cell survival as a result of the Warburg effect<sup><a href="#ref-59">59</a></sup>, mTOR inhibition may actually protect cancer cells from death by conserving essential energy to maintain cell viability.</p><p class="" id=d4428e991>One of the key targets for control by mTORC1, eIF4E, is often expressed at high levels in tumors<sup><a href="#ref-8">8</a></sup>; if its levels exceed those of its mTORC1-regulated inhibitors, 4E-BPs, then inhibition of mTORC1 will not be effective in restricting eIF4E function<sup><a href="#ref-60">60</a></sup>. Alternative ways of impairing eIF4E function may be effective in such settings; possibilities include the use of anti-sense RNAs against its mRNA<sup><a href="#ref-61">61</a></sup>, and blocking its binding to its partner eIF4G<sup><a href="#ref-62">62</a></sup>.</p><p class="" id=d4428e1010>Given, on one hand, the likely importance of mTORC1 signaling in cancer and, on the other hand, the challenges of targeting mTORC1 in a safe and effective way, an alternative strategy is to block the relevant, key events downstream of mTORC1. Kinases that phosphorylate rpS6 are phosphorylated and activated by mTORC1. There are two genes in mammals, often termed <i>S6K1</i> and <i>S6K2</i>, each of which gives rise to two protein isoforms<sup><a href="#ref-63">63</a></sup>. These enzymes should not be confused with the RSKs, which are named after their ability to phosphorylate rpS6 but are regulated by the oncogenic Ras/Raf/MEK/ERK pathway, not by mTORC1<sup><a href="#ref-64">64</a></sup>. Although the functional significance of the phosphorylation of rpS6 is unclear, S6K1 in particular regulates cell growth (size)<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. This almost certainly reflects a role for S6K1 in controlling ribosome biogenesis<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup>, a key process for cell growth control, although additional events may also be involved.</p><p class="" id=d4428e1043>Another route that is being actively explored is to inhibit RNA polymerase I, which makes the main ribosomal RNAs and is switched on by mTORC1 signaling (reviewed in <a href="#ref-69">69</a>). Ribosome production is crucial in cell growth and proliferation and so inhibiting this pathway holds the potential for inhibiting tumor growth. Bywater <i>et al</i>. have developed an inhibitor of Pol I, CX-5461<sup><a href="#ref-70">70</a></sup>, which, when used in combination with everolimus, extended the survival of mice with myc-driven lymphoma<sup><a href="#ref-71">71</a></sup>.</p><p class="" id=d4428e1060>A final issue compromising the efficacy of mTOR inhibitors is that a wide range<sup><a href="#ref-72">72</a>–<a href="#ref-76">76</a></sup> of clinically relevant mutations in mTOR can increase the catalytic activity of mTOR and thus both mTORC1 and mTORC2, thereby reducing the effectiveness of such compounds toward the first two generations of mTOR inhibitors and dual PI3K/mTOR inhibitors in cancer cells<sup><a href="#ref-72">72</a>–<a href="#ref-76">76</a></sup>. This mainly reflects increases in mTOR kinase activity caused by such mutations rather than interference with drug binding as a result of active site mutations<sup><a href="#ref-74">74</a></sup>; since catalytic activity is higher, a dose of inhibitor that is effective against wild-type mTOR will still leave appreciable catalytic activity of the mutant, hyperactive mTOR kinase.</p><p class="" id=d4428e1081>To try to tackle the last of these issues, Rodrik-Outmezguine <i>et al</i>.<sup><a href="#ref-74">74</a></sup> generated rapamycin-resistant breast cancer cell lines (MCF-7 and MDA-MB-468) carrying two mTOR FRB domain mutations (<i>MTOR</i> <sup>A2034V</sup> and <i>MTOR</i><sup>F2108L</sup>) as well as an AZD8055-resistant colony bearing a hyperactive kinase domain mutation (<i>MTOR</i><sup>M2327I</sup>). Careful analysis of the molecular model of mTOR revealed a juxtaposition of the rapamycin and AZD8055 binding sites, prompting the authors to create a powerful bivalent mTOR inhibitor, named RapaLink. This contains both rapamycin and an mTOR kinase inhibitor within the same molecule, connected by a cunningly designed non-perturbing, strain-free cross-linker with the optimum length, which allows the compound to interact with the FRB domain of mTOR through binding to FKBP12 and also to reach the kinase domain of mTOR so that it can also act as an ATP-competitive inhibitor at the same time<sup><a href="#ref-74">74</a></sup> (<a href="#f2">Figure 2</a> and <a href="#f3">Figure 3</a>). Indeed, 3 to 10 nM of either RapaLink-1 or -2 is sufficient to inhibit both mTORC1 and 2 in these mutant cells, as demonstrated by the phosphorylation status of their respective downstream targets, whereas rapamycin and INK128 were unable to effectively block the activities of mTORCs at concentrations of as high as 100 nM<sup><a href="#ref-74">74</a></sup>. Mouse xenografts of MCF-7 cells bearing these mutations are also more sensitive to RapaLink-1 in comparison with rapamycin and AZD8055<sup><a href="#ref-74">74</a></sup>. This landmark study has given birth to a new generation of mTOR inhibitors.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4428e1131>Concluding comments</h2><p class="" id=d4428e1134>It is not surprising, given its importance in normal physiology and in various disease states, that so much attention has been devoted to understanding mTOR signaling pathways and to developing agents that interfere with signaling through mTOR. Despite this effort, the utility of such inhibitors in oncology still appears to be limited for reasons described above. One potential way forward is to develop ways of inhibiting those steps downstream of mTOR, especially mTORC1, that play critical roles in oncogenesis and tumor progression.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d4428e1 class=n-a></a><h2 class=main-title id=d4687>Competing interests</h2><p class=metadata-entry><a name=d4428e105 class=n-a></a><p id=d4428e107> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d4428e1 class=n-a></a><h2 class=main-title id=d4689>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d4428e1141 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d4980>References</h2><div class="section ref-list"><a name=d4428e1141 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d4428e1148 class=n-a></a>Kennedy BK, Lamming DW: The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. <i>Cell Metab.</i> 2016; <b>23</b>(6): 990–1003. <a target=xrefwindow id=d4428e1156 href="http://www.ncbi.nlm.nih.gov/pubmed/27304501">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1159 href="http://dx.doi.org/10.1016/j.cmet.2016.05.009">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1162 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4910876">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d4428e1171 class=n-a></a>Shimobayashi M, Hall MN: Making new contacts: the mTOR network in metabolism and signalling crosstalk. <i>Nat Rev Mol Cell Biol.</i> 2014; <b>15</b>(3): 155–62. <a target=xrefwindow id=d4428e1179 href="http://www.ncbi.nlm.nih.gov/pubmed/24556838">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1182 href="http://dx.doi.org/10.1038/nrm3757">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d4428e1191 class=n-a></a>Kim YC, Guan KL: mTOR: a pharmacologic target for autophagy regulation. <i>J Clin Invest.</i> 2015; <b>125</b>(1): 25–32. <a target=xrefwindow id=d4428e1199 href="http://www.ncbi.nlm.nih.gov/pubmed/25654547">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1202 href="http://dx.doi.org/10.1172/JCI73939">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1205 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4382265">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d4428e1214 class=n-a></a>Jewell JL, Russell RC, Guan KL: Amino acid signalling upstream of mTOR. <i>Nat Rev Mol Cell Biol.</i> 2013; <b>14</b>(3): 133–9. <a target=xrefwindow id=d4428e1222 href="http://www.ncbi.nlm.nih.gov/pubmed/23361334">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1225 href="http://dx.doi.org/10.1038/nrm3522">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1228 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3988467">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d4428e1237 class=n-a></a>Zoncu R, Efeyan A, Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. <i>Nat Rev Mol Cell Biol.</i> 2011; <b>12</b>(1): 21–35. <a target=xrefwindow id=d4428e1245 href="http://www.ncbi.nlm.nih.gov/pubmed/21157483">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1248 href="http://dx.doi.org/10.1038/nrm3025">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1251 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3390257">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d4428e1261 class=n-a></a>Henske EP, Jóźwiak S, Kingswood JC, <i> et al.</i>: Tuberous sclerosis complex. <i>Nat Rev Dis Primers.</i> 2016; <b>2</b>: 16035. <a target=xrefwindow id=d4428e1272 href="http://www.ncbi.nlm.nih.gov/pubmed/27226234">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1275 href="http://dx.doi.org/10.1038/nrdp.2016.35">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d4428e1284 class=n-a></a>Brunn GJ, Hudson CC, Sekulić A, <i> et al.</i>: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. <i>Science.</i> 1997; <b>277</b>(5322): 99–101. <a target=xrefwindow id=d4428e1295 href="http://www.ncbi.nlm.nih.gov/pubmed/9204908">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1298 href="http://dx.doi.org/10.1126/science.277.5322.99">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d4428e1307 class=n-a></a>Siddiqui N, Sonenberg N: Signalling to eIF4E in cancer. <i>Biochem Soc Trans.</i> 2015; <b>43</b>(5): 763–72. <a target=xrefwindow id=d4428e1315 href="http://www.ncbi.nlm.nih.gov/pubmed/26517881">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1318 href="http://dx.doi.org/10.1042/BST20150126">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1321 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4613458">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d4428e1330 class=n-a></a>Huo Y, Iadevaia V, Proud CG: Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis. <i>Biochem Soc Trans.</i> 2011; <b>39</b>(2): 446–50. <a target=xrefwindow id=d4428e1338 href="http://www.ncbi.nlm.nih.gov/pubmed/21428917">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1341 href="http://dx.doi.org/10.1042/BST0390446">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d4428e1350 class=n-a></a>Iadevaia V, Huo Y, Zhang Z, <i> et al.</i>: Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis. <i>Biochem Soc Trans.</i> 2012; <b>40</b>(1): 168–72. <a target=xrefwindow id=d4428e1361 href="http://www.ncbi.nlm.nih.gov/pubmed/22260684">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1364 href="http://dx.doi.org/10.1042/BST20110682">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d4428e1373 class=n-a></a>Gaubitz C, Prouteau M, Kusmider B, <i> et al.</i>: TORC2 Structure and Function. <i>Trends Biochem Sci.</i> 2016; <b>41</b>(6): 532–45. <a target=xrefwindow id=d4428e1384 href="http://www.ncbi.nlm.nih.gov/pubmed/27161823">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1387 href="http://dx.doi.org/10.1016/j.tibs.2016.04.001">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1022752"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e1397 class=n-a></a>Sarbassov DD, Guertin DA, Ali SM, <i> et al.</i>: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. <i>Science.</i> 2005; <b>307</b>(5712): 1098–101. <a target=xrefwindow id=d4428e1408 href="http://www.ncbi.nlm.nih.gov/pubmed/15718470">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1411 href="http://dx.doi.org/10.1126/science.1106148">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1022752">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/720247091"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e1424 class=n-a></a>Humphrey SJ, Yang G, Yang P, <i> et al.</i>: Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. <i>Cell Metab.</i> 2013; <b>17</b>(6): 1009–20. <a target=xrefwindow id=d4428e1435 href="http://www.ncbi.nlm.nih.gov/pubmed/23684622">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1438 href="http://dx.doi.org/10.1016/j.cmet.2013.04.010">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1442 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3690479">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/720247091">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d4428e1455 class=n-a></a>Rosner M, Fuchs C, Siegel N, <i> et al.</i>: Hengstschlager M. Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. <i>Hum Mol Genet.</i> 2009; <b>18</b>(17): 3298–310. <a target=xrefwindow id=d4428e1466 href="http://www.ncbi.nlm.nih.gov/pubmed/19505958">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1469 href="http://dx.doi.org/10.1093/hmg/ddp271">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1473 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2722991">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725693253"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e1482 class=n-a></a>Yang G, Murashige DS, Humphrey SJ, <i> et al.</i>: A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. <i>Cell Rep.</i> 2015; <b>12</b>(6): 937–43. <a target=xrefwindow id=d4428e1493 href="http://www.ncbi.nlm.nih.gov/pubmed/26235620">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1496 href="http://dx.doi.org/10.1016/j.celrep.2015.07.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725693253">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d4428e1509 class=n-a></a>Hers I, Vincent EE, Tavaré JM: Akt signalling in health and disease. <i>Cell Signal.</i> 2011; <b>23</b>(10): 1515–27. <a target=xrefwindow id=d4428e1517 href="http://www.ncbi.nlm.nih.gov/pubmed/21620960">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1520 href="http://dx.doi.org/10.1016/j.cellsig.2011.05.004">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d4428e1529 class=n-a></a>Yuan HX, Guan KL: The SIN1-PH Domain Connects mTORC2 to PI3K. <i>Cancer Discov.</i> 2015; <b>5</b>(11): 1127–9. <a target=xrefwindow id=d4428e1537 href="http://www.ncbi.nlm.nih.gov/pubmed/26526694">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1540 href="http://dx.doi.org/10.1158/2159-8290.CD-15-1125">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4638136">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d4428e1553 class=n-a></a>Forbes SA, Bindal N, Bamford S, <i> et al.</i>: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. <i>Nucleic Acids Res.</i> 2011; <b>39</b>(Database issue): D945–50. <a target=xrefwindow id=d4428e1564 href="http://www.ncbi.nlm.nih.gov/pubmed/20952405">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1567 href="http://dx.doi.org/10.1093/nar/gkq929">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1571 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3013785">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d4428e1580 class=n-a></a>Choo AY, Yoon SO, Kim SG, <i> et al.</i>: Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. <i>Proc Natl Acad Sci U S A.</i> 2008; <b>105</b>(45): 17414–9. <a target=xrefwindow id=d4428e1591 href="http://www.ncbi.nlm.nih.gov/pubmed/18955708">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1594 href="http://dx.doi.org/10.1073/pnas.0809136105">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1598 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2582304">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/3681957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e1607 class=n-a></a>Yip CK, Murata K, Walz T, <i> et al.</i>: Structure of the human mTOR complex I and its implications for rapamycin inhibition. <i>Mol Cell.</i> 2010; <b>38</b>(5): 768–74. <a target=xrefwindow id=d4428e1618 href="http://www.ncbi.nlm.nih.gov/pubmed/20542007">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1621 href="http://dx.doi.org/10.1016/j.molcel.2010.05.017">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1625 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2887672">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/3681957">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726018994"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e1638 class=n-a></a>Aylett CH, Sauer E, Imseng S, <i> et al.</i>: Architecture of human mTOR complex 1. <i>Science.</i> 2016; <b>351</b>(6268): 48–52. <a target=xrefwindow id=d4428e1649 href="http://www.ncbi.nlm.nih.gov/pubmed/26678875">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1652 href="http://dx.doi.org/10.1126/science.aaa3870">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726018994">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d4428e1665 class=n-a></a>Yuan HX, Guan KL: Structural insights of mTOR complex 1. <i>Cell Res.</i> 2016; <b>26</b>(3): 267–8. <a target=xrefwindow id=d4428e1673 href="http://www.ncbi.nlm.nih.gov/pubmed/26794870">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1676 href="http://dx.doi.org/10.1038/cr.2016.10">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1679 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4783463">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/3614966"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e1688 class=n-a></a>Dowling RJ, Topisirovic I, Alain T, <i> et al.</i>: mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. <i>Science.</i> 2010; <b>328</b>(5982): 1172–6. <a target=xrefwindow id=d4428e1699 href="http://www.ncbi.nlm.nih.gov/pubmed/20508131">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1702 href="http://dx.doi.org/10.1126/science.1187532">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1706 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2893390">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/3614966">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d4428e1720 class=n-a></a>Chaturvedi D, Gao X, Cohen MS, <i> et al.</i>: Rapamycin induces transactivation of the EGFR and increases cell survival. <i>Oncogene.</i> 2009; <b>28</b>(9): 1187–96. <a target=xrefwindow id=d4428e1731 href="http://www.ncbi.nlm.nih.gov/pubmed/19151764">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1734 href="http://dx.doi.org/10.1038/onc.2008.490">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1738 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2653860">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13336026"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e1747 class=n-a></a>Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, <i> et al.</i>: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. <i>Cancer Discov.</i> 2011; <b>1</b>(3): 248–59. <a target=xrefwindow id=d4428e1758 href="http://www.ncbi.nlm.nih.gov/pubmed/22140653">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1761 href="http://dx.doi.org/10.1158/2159-8290.CD-11-0085">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3227125">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13336026">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d4428e1778 class=n-a></a>Li J, Kim SG, Blenis J: Rapamycin: one drug, many effects. <i>Cell Metab.</i> 2014; <b>19</b>(3): 373–9. <a target=xrefwindow id=d4428e1786 href="http://www.ncbi.nlm.nih.gov/pubmed/24508508">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1789 href="http://dx.doi.org/10.1016/j.cmet.2014.01.001">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3972801">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d4428e1801 class=n-a></a>Liu R, Proud CG: Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases. <i>Acta Pharmacol Sin.</i> 2016; <b>37</b>(3): 285–94. <a target=xrefwindow id=d4428e1809 href="http://www.ncbi.nlm.nih.gov/pubmed/26806303">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1812 href="http://dx.doi.org/10.1038/aps.2015.123">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1815 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4775846">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d4428e1824 class=n-a></a>Thoreen CC, Sabatini DM: Rapamycin inhibits mTORC1, but not completely. <i>Autophagy.</i> 2009; <b>5</b>(5): 725–6. <a target=xrefwindow id=d4428e1832 href="http://www.ncbi.nlm.nih.gov/pubmed/19395872">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1835 href="http://dx.doi.org/10.4161/auto.5.5.8504">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d4428e1844 class=n-a></a>Sarbassov DD, Ali SM, Sengupta S, <i> et al.</i>: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. <i>Mol Cell.</i> 2006; <b>22</b>(2): 159–68. <a target=xrefwindow id=d4428e1855 href="http://www.ncbi.nlm.nih.gov/pubmed/16603397">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1858 href="http://dx.doi.org/10.1016/j.molcel.2006.03.029">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d4428e1868 class=n-a></a>Julien LA, Carriere A, Moreau J, <i> et al.</i>: mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. <i>Mol Cell Biol.</i> 2010; <b>30</b>(4): 908–21. <a target=xrefwindow id=d4428e1879 href="http://www.ncbi.nlm.nih.gov/pubmed/19995915">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1882 href="http://dx.doi.org/10.1128/MCB.00601-09">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1886 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2815569">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d4428e1895 class=n-a></a>Xie J, Proud CG: Signaling crosstalk between the mTOR complexes. <i>Translation (Austin).</i> 2014; <b>2</b>(1): e28174. <a target=xrefwindow id=d4428e1903 href="http://www.ncbi.nlm.nih.gov/pubmed/26779402">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1906 href="http://dx.doi.org/10.4161/trla.28174">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1909 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4705829">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d4428e1918 class=n-a></a>Schuler W, Sedrani R, Cottens S, <i> et al.</i>: SDZ RAD, a new rapamycin derivative: pharmacological properties <i>in vitro</i> and <i>in vivo</i>. <i>Transplantation.</i> 1997; <b>64</b>(1): 36–42. <a target=xrefwindow id=d4428e1936 href="http://www.ncbi.nlm.nih.gov/pubmed/9233698">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1939 href="http://dx.doi.org/10.1097/00007890-199707150-00008">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d4428e1948 class=n-a></a>Schuurman HJ, Cottens S, Fuchs S, <i> et al.</i>: SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. <i>Transplantation.</i> 1997; <b>64</b>(1): 32–5. <a target=xrefwindow id=d4428e1959 href="http://www.ncbi.nlm.nih.gov/pubmed/9233697">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1962 href="http://dx.doi.org/10.1097/00007890-199707150-00007">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d4428e1971 class=n-a></a>Raynaud FI, Eccles SA, Patel S, <i> et al.</i>: Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. <i>Mol Cancer Ther.</i> 2009; <b>8</b>(7): 1725–38. <a target=xrefwindow id=d4428e1982 href="http://www.ncbi.nlm.nih.gov/pubmed/19584227">PubMed Abstract </a> | <a target=xrefwindow id=d4428e1985 href="http://dx.doi.org/10.1158/1535-7163.MCT-08-1200.">Publisher Full Text </a> | <a target=xrefwindow id=d4428e1989 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2718129">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d4428e1998 class=n-a></a>Maira S, Stauffer F, Brueggen J, <i> et al.</i>: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity. <i>Mol Cancer Ther.</i> 2008; <b>7</b>(7): 1851–63. <a target=xrefwindow id=d4428e2012 href="http://www.ncbi.nlm.nih.gov/pubmed/18606717">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2016 href="http://dx.doi.org/10.1158/1535-7163.MCT-08-0017">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2019 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4012430">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d4428e2029 class=n-a></a>Aziz SA, Jilaveanu LB, Zito C, <i> et al.</i>: Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. <i>Clin Cancer Res.</i> 2010; <b>16</b>(24): 6029–39. <a target=xrefwindow id=d4428e2040 href="http://www.ncbi.nlm.nih.gov/pubmed/21169255">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2043 href="http://dx.doi.org/10.1158/1078-0432.CCR-10-1490">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2047 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3058635">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d4428e2056 class=n-a></a>Engelman JA, Chen L, Tan X, <i> et al.</i>: Effective use of PI3K and MEK inhibitors to treat mutant <i>Kras</i> G12D and <i>PIK3CA</i> H1047R murine lung cancers. <i>Nat Med.</i> 2008; <b>14</b>(12): 1351–6. <a target=xrefwindow id=d4428e2074 href="http://www.ncbi.nlm.nih.gov/pubmed/19029981">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2077 href="http://dx.doi.org/10.1038/nm.1890">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2080 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2683415">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1789957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2089 class=n-a></a>Knight SD, Adams ND, Burgess JL, <i> et al.</i>: Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. <i>ACS Med Chem Lett.</i> 2010; <b>1</b>(1): 39–43. <a target=xrefwindow id=d4428e2100 href="http://www.ncbi.nlm.nih.gov/pubmed/24900173">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2103 href="http://dx.doi.org/10.1021/ml900028r">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2107 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4007793">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1789957">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718317390"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2120 class=n-a></a>Yu P, Laird AD, Du X, <i> et al.</i>: Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. <i>Mol Cancer Ther.</i> 2014; <b>13</b>(5): 1078–91. <a target=xrefwindow id=d4428e2131 href="http://www.ncbi.nlm.nih.gov/pubmed/24634413">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2134 href="http://dx.doi.org/10.1158/1535-7163.MCT-13-0709">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718317390">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d4428e2147 class=n-a></a>Garlich JR, De P, Dey N, <i> et al.</i>: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. <i>Cancer Res.</i> 2008; <b>68</b>(1): 206–15. <a target=xrefwindow id=d4428e2158 href="http://www.ncbi.nlm.nih.gov/pubmed/18172313">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2161 href="http://dx.doi.org/10.1158/0008-5472.CAN-07-0669">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1125907"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2170 class=n-a></a>Apsel B, Blair JA, Gonzalez B, <i> et al.</i>: Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. <i>Nat Chem Biol.</i> 2008; <b>4</b>(11): 691–9. <a target=xrefwindow id=d4428e2181 href="http://www.ncbi.nlm.nih.gov/pubmed/18849971">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2184 href="http://dx.doi.org/10.1038/nchembio.117">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2188 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2880455">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1125907">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d4428e2202 class=n-a></a>Feldman ME, Apsel B, Uotila A, <i> et al.</i>: Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. <i>PLoS Biol.</i> 2009; <b>7</b>(2): e38. <a target=xrefwindow id=d4428e2213 href="http://www.ncbi.nlm.nih.gov/pubmed/19209957">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2216 href="http://dx.doi.org/10.1371/journal.pbio.1000038">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2637922">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/2630962"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2229 class=n-a></a>Hsieh AC, Costa M, Zollo O, <i> et al.</i>: Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. <i>Cancer Cell.</i> 2010; <b>17</b>(3): 249–61. <a target=xrefwindow id=d4428e2240 href="http://www.ncbi.nlm.nih.gov/pubmed/20227039">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2243 href="http://dx.doi.org/10.1016/j.ccr.2010.01.021">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2247 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2901095">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/2630962">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/14025956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2260 class=n-a></a>Hsieh AC, Liu Y, Edlind MP, <i> et al.</i>: The translational landscape of mTOR signalling steers cancer initiation and metastasis. <i>Nature.</i> 2012; <b>485</b>(7396): 55–61. <a target=xrefwindow id=d4428e2271 href="http://www.ncbi.nlm.nih.gov/pubmed/22367541">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2274 href="http://dx.doi.org/10.1038/nature10912">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2278 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3663483">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/14025956">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d4428e2291 class=n-a></a>Thoreen CC, Kang SA, Chang JW, <i> et al.</i>: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. <i>J Biol Chem.</i> 2009; <b>284</b>(12): 8023–32. <a target=xrefwindow id=d4428e2302 href="http://www.ncbi.nlm.nih.gov/pubmed/19150980">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2305 href="http://dx.doi.org/10.1074/jbc.M900301200">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2309 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2658096">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718400680"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2318 class=n-a></a>Liu Q, Xu C, Kirubakaran S, <i> et al.</i>: Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. <i>Cancer Res.</i> 2013; <b>73</b>(8): 2574–86. <a target=xrefwindow id=d4428e2329 href="http://www.ncbi.nlm.nih.gov/pubmed/23436801">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2332 href="http://dx.doi.org/10.1158/0008-5472.CAN-12-1702">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2336 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3760004">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718400680">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d4428e2349 class=n-a></a>García-Martínez JM, Moran J, Clarke RG, <i> et al.</i>: Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). <i>Biochem J.</i> 2009; <b>421</b>(1): 29–42. <a target=xrefwindow id=d4428e2360 href="http://www.ncbi.nlm.nih.gov/pubmed/19402821">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2363 href="http://dx.doi.org/10.1042/BJ20090489">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2367 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2708931">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d4428e2377 class=n-a></a>Malagu K, Duggan H, Menear K, <i> et al.</i>: The discovery and optimisation of pyrido[2,3-<i>d</i>]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. <i>Bioorg Med Chem Lett.</i> 2009; <b>19</b>(20): 5950–3. <a target=xrefwindow id=d4428e2391 href="http://www.ncbi.nlm.nih.gov/pubmed/19762236">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2395 href="http://dx.doi.org/10.1016/j.bmcl.2009.08.038">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d4428e2404 class=n-a></a>Yu K, Toral-Barza L, Shi C, <i> et al.</i>: Biochemical, cellular, and <i>in vivo</i> activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. <i>Cancer Res.</i> 2009; <b>69</b>(15): 6232–40. <a target=xrefwindow id=d4428e2418 href="http://www.ncbi.nlm.nih.gov/pubmed/19584280">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2422 href="http://dx.doi.org/10.1158/0008-5472.CAN-09-0299">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d4428e2431 class=n-a></a>Chresta CM, Davies BR, Hickson I, <i> et al.</i>: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with <i>in vitro</i> and <i>in vivo</i> antitumor activity. <i>Cancer Res.</i> 2010; <b>70</b>(1): 288–98. <a target=xrefwindow id=d4428e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/20028854">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2452 href="http://dx.doi.org/10.1158/0008-5472.CAN-09-1751">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725573792"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2461 class=n-a></a>Pike KG, Malagu K, Hummersone MG, <i> et al.</i>: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. <i>Bioorg Med Chem Lett.</i> 2013; <b>23</b>(5): 1212–6. <a target=xrefwindow id=d4428e2472 href="http://www.ncbi.nlm.nih.gov/pubmed/23375793">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2475 href="http://dx.doi.org/10.1016/j.bmcl.2013.01.019">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725573792">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d4428e2488 class=n-a></a>Shapiro AM, Lakey JR, Ryan EA, <i> et al.</i>: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. <i>N Engl J Med.</i> 2000; <b>343</b>(4): 230–8. <a target=xrefwindow id=d4428e2499 href="http://www.ncbi.nlm.nih.gov/pubmed/10911004">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2502 href="http://dx.doi.org/10.1056/NEJM200007273430401">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d4428e2511 class=n-a></a>Ryan EA, Paty BW, Senior PA, <i> et al.</i>: Five-year follow-up after clinical islet transplantation. <i>Diabetes.</i> 2005; <b>54</b>(7): 2060–9. <a target=xrefwindow id=d4428e2522 href="http://www.ncbi.nlm.nih.gov/pubmed/15983207">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2525 href="http://dx.doi.org/10.2337/diabetes.54.7.2060">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d4428e2535 class=n-a></a>Bell E, Cao X, Moibi JA, <i> et al.</i>: Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. <i>Diabetes.</i> 2003; <b>52</b>(11): 2731–9. <a target=xrefwindow id=d4428e2546 href="http://www.ncbi.nlm.nih.gov/pubmed/14578291">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2549 href="http://dx.doi.org/10.2337/diabetes.52.11.2731">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d4428e2558 class=n-a></a>Zhang N, Su D, Qu S, <i> et al.</i>: Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. <i>Diabetes.</i> 2006; <b>55</b>(9): 2429–36. <a target=xrefwindow id=d4428e2569 href="http://www.ncbi.nlm.nih.gov/pubmed/16936190">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2572 href="http://dx.doi.org/10.2337/db06-0173">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d4428e2581 class=n-a></a>Barlow AD, Xie J, Moore CE, <i> et al.</i>: Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2). <i>Diabetologia.</i> 2012; <b>55</b>(5): 1355–65. <a target=xrefwindow id=d4428e2592 href="http://www.ncbi.nlm.nih.gov/pubmed/22314813">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2595 href="http://dx.doi.org/10.1007/s00125-012-2475-7">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2599 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3328678">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718906859"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2608 class=n-a></a>Huang S, Yang ZJ, Yu C, <i> et al.</i>: Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. <i>J Biol Chem.</i> 2011; <b>286</b>(46): 40002–12. <a target=xrefwindow id=d4428e2619 href="http://www.ncbi.nlm.nih.gov/pubmed/21949121">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2622 href="http://dx.doi.org/10.1074/jbc.M111.297432">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2626 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3220585">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718906859">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/721619280"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2639 class=n-a></a>Willems L, Chapuis N, Puissant A, <i> et al.</i>: The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. <i>Leukemia.</i> 2012; <b>26</b>(6): 1195–202. <a target=xrefwindow id=d4428e2650 href="http://www.ncbi.nlm.nih.gov/pubmed/22143671">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2653 href="http://dx.doi.org/10.1038/leu.2011.339">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/721619280">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d4428e2666 class=n-a></a>Koppenol WH, Bounds PL, Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. <i>Nat Rev Cancer.</i> 2011; <b>11</b>(5): 325–37. <a target=xrefwindow id=d4428e2674 href="http://www.ncbi.nlm.nih.gov/pubmed/21508971">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2677 href="http://dx.doi.org/10.1038/nrc3038">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/719410573"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2687 class=n-a></a>Alain T, Morita M, Fonseca BD, <i> et al.</i>: eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. <i>Cancer Res.</i> 2012; <b>72</b>(24): 6468–76. <a target=xrefwindow id=d4428e2698 href="http://www.ncbi.nlm.nih.gov/pubmed/23100465">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2701 href="http://dx.doi.org/10.1158/0008-5472.CAN-12-2395">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/719410573">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718183327"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2714 class=n-a></a>Jacobson BA, Thumma SC, Jay-Dixon J, <i> et al.</i>: Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide. <i>PLoS One.</i> 2013; <b>8</b>(11): e81669. <a target=xrefwindow id=d4428e2725 href="http://www.ncbi.nlm.nih.gov/pubmed/24260583">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2728 href="http://dx.doi.org/10.1371/journal.pone.0081669">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2732 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3832430">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718183327">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1065728"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2745 class=n-a></a>Moerke NJ, Aktas H, Chen H, <i> et al.</i>: Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. <i>Cell.</i> 2007; <b>128</b>(2): 257–67. <a target=xrefwindow id=d4428e2756 href="http://www.ncbi.nlm.nih.gov/pubmed/17254965">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2759 href="http://dx.doi.org/10.1016/j.cell.2006.11.046">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1065728">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d4428e2772 class=n-a></a>Proud CG: mTORC1 signalling and mRNA translation. <i>Biochem Soc Trans.</i> 2009; <b>37</b>(Pt 1): 227–31. <a target=xrefwindow id=d4428e2780 href="http://www.ncbi.nlm.nih.gov/pubmed/19143637">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2783 href="http://dx.doi.org/10.1042/BST0370227">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d4428e2792 class=n-a></a>Romeo Y, Zhang X, Roux PP: Regulation and function of the RSK family of protein kinases. <i>Biochem J.</i> 2012; <b>441</b>(12): 553–69. <a target=xrefwindow id=d4428e2800 href="http://www.ncbi.nlm.nih.gov/pubmed/22187936">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2803 href="http://dx.doi.org/10.1042/BJ20110289">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d4428e2812 class=n-a></a>Montagne J, Stewart MJ, Stocker H, <i> et al.</i>: <i>Drosophila</i> S6 kinase: a regulator of cell size. <i>Science.</i> 1999; <b>285</b>(5436): 2126–9. <a target=xrefwindow id=d4428e2826 href="http://www.ncbi.nlm.nih.gov/pubmed/10497130">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2830 href="http://dx.doi.org/10.1126/science.285.5436.2126">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d4428e2840 class=n-a></a>Shima H, Pende M, Chen Y, <i> et al.</i>: Disruption of the p70<sup>s6k</sup>/p85<sup>s6k</sup> gene reveals a small mouse phenotype and a new functional S6 kinase. <i>EMBO J.</i> 1998; <b>17</b>(22): 6649–59. <a target=xrefwindow id=d4428e2858 href="http://www.ncbi.nlm.nih.gov/pubmed/9822608">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2861 href="http://dx.doi.org/10.1093/emboj/17.22.6649">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2864 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1171010">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717971813"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2873 class=n-a></a>Chauvin C, Koka V, Nouschi A, <i> et al.</i>: Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. <i>Oncogene.</i> 2014; <b>33</b>(4): 474–83. <a target=xrefwindow id=d4428e2884 href="http://www.ncbi.nlm.nih.gov/pubmed/23318442">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2887 href="http://dx.doi.org/10.1038/onc.2012.606">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717971813">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d4428e2900 class=n-a></a>Hannan KM, Brandenburger Y, Jenkins A, <i> et al.</i>: mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. <i>Mol Cell Biol.</i> 2003; <b>23</b>(23): 8862–77. <a target=xrefwindow id=d4428e2911 href="http://www.ncbi.nlm.nih.gov/pubmed/14612424">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2914 href="http://dx.doi.org/10.1128/MCB.23.23.8862-8877.2003">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2918 href="http://www.ncbi.nlm.nih.gov/pmc/articles/262650">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d4428e2927 class=n-a></a>Iadevaia V, Liu R, Proud CG: mTORC1 signaling controls multiple steps in ribosome biogenesis. <i>Semin Cell Dev Biol.</i> 2014; <b>36</b>: 113–20. <a target=xrefwindow id=d4428e2935 href="http://www.ncbi.nlm.nih.gov/pubmed/25148809">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2938 href="http://dx.doi.org/10.1016/j.semcdb.2014.08.004">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717952850"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2947 class=n-a></a>Bywater MJ, Poortinga G, Sanij E, <i> et al.</i>: Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. <i>Cancer Cell.</i> 2012; <b>22</b>(1): 51–65. <a target=xrefwindow id=d4428e2958 href="http://www.ncbi.nlm.nih.gov/pubmed/22789538">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2961 href="http://dx.doi.org/10.1016/j.ccr.2012.05.019">Publisher Full Text </a> | <a target=xrefwindow id=d4428e2965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3749732">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717952850">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725869601"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e2978 class=n-a></a>Devlin JR, Hannan KM, Hein N, <i> et al.</i>: Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. <i>Cancer Discov.</i> 2016; <b>6</b>(1): 59–70. <a target=xrefwindow id=d4428e2989 href="http://www.ncbi.nlm.nih.gov/pubmed/26490423">PubMed Abstract </a> | <a target=xrefwindow id=d4428e2992 href="http://dx.doi.org/10.1158/2159-8290.CD-14-0673">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725869601">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725714484"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e3006 class=n-a></a>Ghosh AP, Marshall CB, Coric T, <i> et al.</i>: Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. <i>Oncotarget.</i> 2015; <b>6</b>(20): 17895–910. <a target=xrefwindow id=d4428e3017 href="http://www.ncbi.nlm.nih.gov/pubmed/26255626">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3020 href="http://dx.doi.org/10.18632/oncotarget.4963">Publisher Full Text </a> | <a target=xrefwindow id=d4428e3024 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4627224">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725714484">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718315323"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e3037 class=n-a></a>Grabiner BC, Nardi V, Birsoy K, <i> et al.</i>: A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. <i>Cancer Discov.</i> 2014; <b>4</b>(5): 554–63. <a target=xrefwindow id=d4428e3048 href="http://www.ncbi.nlm.nih.gov/pubmed/24631838">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3051 href="http://dx.doi.org/10.1158/2159-8290.CD-13-0929">Publisher Full Text </a> | <a target=xrefwindow id=d4428e3055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4012430">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718315323">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726384027"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e3068 class=n-a></a>Rodrik-Outmezguine VS, Okaniwa M, Yao Z, <i> et al.</i>: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. <i>Nature.</i> 2016; <b>534</b>(7606): 272–6. <a target=xrefwindow id=d4428e3079 href="http://www.ncbi.nlm.nih.gov/pubmed/27279227">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3082 href="http://dx.doi.org/10.1038/nature17963">Publisher Full Text </a> | <a target=xrefwindow id=d4428e3086 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4902179">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726384027">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725311807"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e3099 class=n-a></a>Sato T, Nakashima A, Guo L, <i> et al.</i>: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. <i>Oncogene.</i> 2010; <b>29</b>(18): 2746–52. <a target=xrefwindow id=d4428e3110 href="http://www.ncbi.nlm.nih.gov/pubmed/20190810">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3113 href="http://dx.doi.org/10.1038/onc.2010.28">Publisher Full Text </a> | <a target=xrefwindow id=d4428e3117 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2953941">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725311807">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718311201"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4428e3130 class=n-a></a>Wagle N, Grabiner BC, van Allen EM, <i> et al.</i>: Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. <i>Cancer Discov.</i> 2014; <b>4</b>(5): 546–53. <a target=xrefwindow id=d4428e3141 href="http://www.ncbi.nlm.nih.gov/pubmed/24625776">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3144 href="http://dx.doi.org/10.1158/2159-8290.CD-13-0353">Publisher Full Text </a> | <a target=xrefwindow id=d4428e3148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4122326">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718311201">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d4428e3161 class=n-a></a>Baker H, Sidorowicz A, Sehgal SN, <i> et al.</i>: Rapamycin (AY-22,989), a new antifungal antibiotic. III. <i>In vitro</i> and <i>in vivo</i> evaluation. <i>J Antibiot (Tokyo).</i> 1978; <b>31</b>(6): 539–45. <a target=xrefwindow id=d4428e3179 href="http://www.ncbi.nlm.nih.gov/pubmed/28309">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3182 href="http://dx.doi.org/10.7164/antibiotics.31.539">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d4428e3192 class=n-a></a>Sehgal SN, Baker H, Vézina C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. <i>J Antibiot (Tokyo).</i> 1975; <b>28</b>(10): 727–32. <a target=xrefwindow id=d4428e3200 href="http://www.ncbi.nlm.nih.gov/pubmed/1102509">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3203 href="http://dx.doi.org/10.7164/antibiotics.28.727">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d4428e3212 class=n-a></a>Singh K, Sun S, Vézina C: Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action. <i>J Antibiot (Tokyo).</i> 1979; <b>32</b>(6): 630–45. <a target=xrefwindow id=d4428e3220 href="http://www.ncbi.nlm.nih.gov/pubmed/381274">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3223 href="http://dx.doi.org/10.7164/antibiotics.32.630">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d4428e3232 class=n-a></a>Vézina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. <i>J Antibiot (Tokyo).</i> 1975; <b>28</b>(10): 721–6. <a target=xrefwindow id=d4428e3240 href="http://www.ncbi.nlm.nih.gov/pubmed/1102508">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3243 href="http://dx.doi.org/10.7164/antibiotics.28.721">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d4428e3252 class=n-a></a>Geoerger B, Kerr K, Tang CB, <i> et al.</i>: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. <i>Cancer Res.</i> 2001; <b>61</b>(4): 1527–32. <a target=xrefwindow id=d4428e3263 href="http://www.ncbi.nlm.nih.gov/pubmed/11245461">PubMed Abstract </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d4428e3272 class=n-a></a>Carayol N, Vakana E, Sassano A, <i> et al.</i>: Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. <i>Proc Natl Acad Sci U S A.</i> 2010; <b>107</b>(28): 12469–74. <a target=xrefwindow id=d4428e3283 href="http://www.ncbi.nlm.nih.gov/pubmed/20616057">PubMed Abstract </a> | <a target=xrefwindow id=d4428e3286 href="http://dx.doi.org/10.1073/pnas.1005114107">Publisher Full Text </a> | <a target=xrefwindow id=d4428e3290 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2906574">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2078/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2078/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Nutrition and Metabolism, South Australian Health and Medical research Institute, Adelaide, SA, Australia<br/> <sup>2</sup> School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2078/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 25 Aug 2016, 5:2078 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9207.1">https://doi.org/10.12688/f1000research.9207.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Xie J <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=9910 data-id=9207 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9207.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2078/v1/pdf?article_uuid=3c0c7d27-4a00-4574-a4fb-aac030823eb5" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9207.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Xie J, Wang X and Proud CG. mTOR inhibitors in cancer therapy [version 1; peer review: 3 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2078 (<a href="https://doi.org/10.12688/f1000research.9207.1" target=_blank>https://doi.org/10.12688/f1000research.9207.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9207 id=mobile-track-article-signin-9207 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9207?target=/articles/5-2078/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9910 /> <input name=articleId type=hidden value=9207 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Mario Pende</strong>, Institut Necker-Enfants Malades, Inserm, Paris Descartes University, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Andrew Tee</strong>, Institute of Cancer & Genetics, Cardiff University School of Medicine, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Joseph Avruch</strong>, Department of Molecular Biology, Massachusetts General Hospital, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2078/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2078/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16708-15891></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16707-15892></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=2001-15893></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2078/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>25 Aug 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Mario Pende</strong>, Institut Necker-Enfants Malades, Inserm, Paris Descartes University, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Andrew Tee</strong>, Institute of Cancer & Genetics, Cardiff University School of Medicine, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Joseph Avruch</strong>, Department of Molecular Biology, Massachusetts General Hospital, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2078/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2078/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "mTOR inhibitors in cancer therapy".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2078/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2078/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2078/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Xie J et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2078/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2078",
            templates : {
                twitter : "mTOR inhibitors in cancer therapy. Xie J et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2078/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: mTOR inhibitors in cancer therapy", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: mTOR inhibitors in cancer therapy", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9207/9910")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "9910");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "15891": 0,
                           "15892": 0,
                           "15893": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "138c3d4c-f4e1-467d-a766-fe46e268fe0a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2078.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2078.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2078.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2078.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2078.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>